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ABSTRACT
TRAP150 has been identified as a subunit of the
transcription regulatory complex TRAP/Mediator,
and also a component of the spliceosome. The
exact function of TRAP150, however, remains
unclear. We recently identified TRAP150 by its asso-
ciation with the mRNA export factor TAP. TRAP150
contains an arginine/serine-rich domain and has
sequence similarity with the cell death-promoting
transcriptional repressor BCLAF1. We found that
TRAP150 co-localizes with splicing factors in
nuclear speckles, and is required for pre-mRNA
splicing and activates splicing in vivo. TRAP150
remains associated with the spliced mRNA after
splicing, and accordingly, it interacts with the
integral exon junction complex. Unexpectedly,
when tethered to a precursor mRNA, TRAP150
can trigger mRNA degradation in the nucleus.
However, unlike nonsense-mediated decay,
TRAP150-mediated mRNA decay is irrespective of
the presence of upstream stop codons and occurs
in the nucleus. Moreover, TRAP150 activates
pre-mRNA splicing and induces mRNA degradation
by its separable functional domains. Therefore,
TRAP150 represents a multi-functional protein
involved in nuclear mRNA metabolism.
INTRODUCTION
Eukaryotic mRNA biogenesis comprises several post-
transcriptional events, including pre-mRNA processing,
mRNA export, surveillance and turnover control. Each
individual step is carried out by specialized molecular
machinery, but all steps are interconnected and collec-
tively form an intricate network, with which cells achieve
faithful and eﬃcient gene expression (1,2).
During mRNA synthesis, the transcription machinery
recruits RNA processing factors for capping, splicing and
polyadenylation of the growing transcripts. The recruit-
ment of speciﬁc factors may inﬂuence regulated precursor
mRNA (pre-mRNA) processing events, such as alterna-
tive splice site selection or polyadenylation site utilization
(3). Pre-mRNA splicing is catalyzed by the spliceosome, a
large ribonucleoprotein (RNP) complex containing ﬁve
small nuclear RNAs and  150 protein factors (4). The
spliceosome assembles anew on each pre-mRNA during
splicing. Upon completion of splicing, the multiprotein
exon junction complex (EJC) forms  20nt upstream of
each splice junction of the spliced mRNA (5,6). The EJC
recruits or interacts with factors that facilitate subsequent
mRNA export and surveillance steps. The most well-
characterized mRNA surveillance pathway is nonsense-
mediated decay (NMD), which allows detection and
elimination of mRNAs harboring premature termination
codons (PTCs) and thereby prevents their translation
(7,8).
Individual EJC components may function in
pre-mRNA processing or act as an eﬀector in subsequent
mRNA maturation steps. Several EJC factors, such as
UAP56, RNPS1, SRm160 and Pnn/DRS, physically asso-
ciate with the pre-mRNA during splicing (5). These
factors may be critical for pre-mRNA splicing or partici-
pate in diﬀerent aspects of splicing regulation (9–12).
Following splicing, some of the EJC-associated factors,
such as the export receptor TAP and RNA-binding
protein Aly/REF, act to lead mRNA export (13).
Moreover, the core factors of the EJC, Y14/Magoh,
recruit the NMD factor Upf3 in the nucleus. Upf3
accompanies the mRNA to the cytoplasm and
sequentially recruits Upf2 and the SURF complex (con-
sisting of UPF1, SMG1 and the release factors eRF1 and
eRF3) to the mRNA (14). Upon phosphorylation of Upf1
by SMG1, the EJC inhibits translation and recruits
mRNA degradation factors to destroy PTC-containing
mRNAs (14,15). Therefore, the EJC not only provides a
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biogenesis but also provides a platform for cellular regu-
lation of post-transcriptional gene expression.
We initially set out to identify protein partners of TAP,
which is a critical factor for general mRNA export. One of
the identiﬁed candidates was TRAP150, a potential tran-
scription and splicing factor. In this study, we demons-
trated a role for TRAP150 in pre-mRNA splicing and,
unexpectedly, in nuclear mRNA degradation.
MATERIALS AND METHODS
Plasmids
The complementary DNA (cDNA) encoding full-length
TRAP150 was polymerase chain reaction (PCR)-ampliﬁed
from a human fetal brain cDNA library (Clontech) using
speciﬁc primers. The PCR product was inserted into
a pcDNA3.1 (Invitrogen)-based vector in-frame with
the sequence encoding the FLAG tag to generate
pcDNA-TRAP150-FLAG. Analogously, expression
vectors encoding each of the truncated TRAP150
proteins (Figure 3C) were generated. The cDNAs
encoding full-length or truncated TRAP150 proteins
were each cloned into pCEP4 (Invitrogen), yielding the
expression vectors for hemagglutinin (HA)-tagged
proteins. The DNA fragments containing the HA and
full-length or truncated TRAP150 sequences were sub-
cloned into pMCP (16) to generate the vectors for
expressing the MS2 coat protein (MCP)-fusion proteins.
To raise an antiserum against TRAP150, the
TRAP150NC DNA fragment was inserted in-frame
into pGEX-5X (GE Healthcare) and pET29b (Novagen)
to generate the bacterial expression vector for the
glutathione S-transferase (GST) and 6  histidine (His)-
fused TRAP150NC protein, respectively. The
BCLAF1 and MLN51 cDNAs were PCR-ampliﬁed and
cloned into pcDNA3.1 and pCEP4 to generate the expres-
sion vectors for FLAG- and HA-tagged proteins, respec-
tively. The plasmids expressing FLAG-tagged Aly/REF,
SRm160, Y14, TAP, Upf3B, RNPS1, hUpf1,
hUpf1-R844C and the reporter plasmids used for NMD
assays (including bUAA-6bs, bUAC-6bs, bG, bwt and
b39) were kind gifts from Jens Lykke-Anderson
(University of Colorado, Boulder, CO, USA; Ref. 17).
The cDNA fragment encoding eIF4AIII protein was
PCR ampliﬁed and cloned into pCEP4 vector to
generate HA-tagged eIF4AIII expression vector. The
b1 reporter was created by substitution of the Hind
III/BamH I cDNA fragment corresponding to the
spliced b-globin reporter mRNA. The b1-50m reporter
was generated by using PCR-based site-directed
mutagenesis (Stratagene).
Antibody preparation
The GST and 6  His-TRAP150NC recombinant
proteins were overexpressed in Escherichia coli and
puriﬁed according to the manufacturer’s instructions. 6 
His-TRAP150NC was used as antigen to immunize
rabbits. Antibodies were aﬃnity-puriﬁed against
recombinant GST-TRAP150NC protein according to
the method described previously (18).
Cell culture and transfection
HEK293, HeLa, Tet-Oﬀ HeLa and NIH3T3 cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal bovine serum and penicillin/
streptomycin/glutamine (Invitrogen). Transfections were
performed using Lipofectamine 2000 (Invitrogen) for
24h. For immunoprecipitation experiments, HEK293
cells were transfected using calcium phosphate. At 16h
post-transfection, cells were placed in fresh medium and
cultured for another 24h before harvest.
Indirect immunoﬂuorescence and heterokaryon assay
HeLa cells were ﬁxed by 2% formaldehyde in phosphate-
buﬀered saline (PBS) for 20min and subsequently
permeabilized with 100% acetone at 4 C for 3min. The
primary antibodies used included monoclonal anti-FLAG
(M2; 1:300 dilution; Sigma) and anti-SC35 (4.6mg/ml;
Sigma), and polyclonal anti-HA (1:100 dilution;
Covance Inc.) and aﬃnity-puriﬁed polyclonal anti-
TRAP150 (1:100 dilution). The secondary antibodies
used were ﬂuorescein-conjugated anti-rabbit IgG (12mg/
ml; Cappel Laboratories) for polyclonal primary anti-
bodies, and rhodamine-conjugated anti-mouse IgG
(7.5mg/ml, Cappel Laboratories) for monoclonal
primary antibodies. The specimens were observed using
a Zeiss Axiovert 200M inverted research-grade ﬂuo-
rescence microscope coupled with an image analysis
system.
The heterokaryon assay was performed as described
(17) with a minor modiﬁcation. Brieﬂy, HeLa cells were
co-transfected with the vectors encoding TRAP150-
FLAG and GFP-hnRNP A1 or GFP hnRNP C1. At
48h post-transfection, HeLa cells were co-cultured with
NIH3T3 cells and treated with cycloheximide (Sigma) at
a concentration of 50mg/ml for 3h and 100mg/ml for
another 30min. To induce cell fusion, 50% polyethylene
glycol 3350 (Sigma) was added to the co-culture for 2min.
The cells were subsequently returned to fresh media con-
taining 100mg/ml cycloheximide for 3 or 16h. Indirect
immunoﬂuorescence was performed as described above.
To distinguish HeLa from mouse NIH 3T3 cells, the
cells were counterstained with Hoechst 33258 (5mg/ml;
Sigma).
In vivo splicing and real-time-PCR
The splicing reporter pSV40-CAT(In) (18) was
co-transfected with eﬀector expression vectors (2mg) into
HeLa cells in 3.5-cm dishes at 80–90% conﬂuency. At 24h
post-transfection, RNA samples were harvested from cells
using TRIzol reagent (Invitrogen) and treated with
RQ-DNase1 (Promega). Subsequently, RNAs were con-
verted to ﬁrst-strand cDNAs using SuperScript III reverse
transcriptase (Invitrogen) using the 30 primer 50-GCAAG
CTTCACTCCAGAGCGATG-30 complementary to the
CAT transcript. Subsequently, PCR and Southern
blotting were performed using speciﬁc primers as
described (18).
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spliceosome
Preparation of nuclear extracts was essentially according
to Hirose et al. (19), except that calcium phosphate was
used for cell transfection. In general, HEK293 cells grown
in 15-cm dishes at 70–80% conﬂuency were transfected
with 50mg of expression vector encoding either
FLAG-tagged full-length or truncated TRAP150. At
16h post-transfection, medium was refreshed and cells
were incubated for another 24h. For preparation of the
TRAP150-depleted nuclear extract, HeLa cells grown in
15-cm dishes at  60% conﬂuency were transfected with
50nM si-TRAP150-J5 using Lipofectamine 2000. At 48h
post-transfaction, cells were harvested for nuclear extract
preparation as described (19).
In vitro splicing was performed essentially as described
(20) using
32P-labeled PIP85a pre-mRNA (gift of
Benjamin J. Blencowe, Toronto University) as substrate.
The reaction was incubated at 30 C for 90min, followed
by subsequent incubation with anti-FLAG M2 agarose
(Sigma) or anti-Sm (Y12, gift of Joan Steitz, Yale
University) bound to protein A-Sepharose at 4 C for 2h
(18). The beads were washed extensively with NET-2
buﬀer (50mM Tris–HCl, pH 7.4 and 150mM NaCl) con-
taining 0.05% NP-40. Reactions were treated with 10mg/
ml proteinase K prior to RNA collection. RNAs were
analyzed by electrophoresis on 6% denaturing
polyacrylamide gels.
Immunoprecipitation
For co-immunoprecipitation, HEK293 cells grown on
a 10-cm dish were co-transfected with 14mgo f
pCEP4-TRAP150-HA or pCEP4-eIF4AIII-HA and 7mg
of vector encoding for a Flag-tagged EJC or NMD factor
or TRAP150 by calcium phosphate method. Cells were
lysed in 1ml of hypotonic lysis buﬀer containing 10mM
Tris–HCl, pH 7.5, 10mM NaCl, 10mM EDTA, 0.5%
Triton X-100, and 1  protease inhibitor cocktail
(Roche) on ice for 15min. Subsequently, additional
NaCl was added to the lysate to a ﬁnal concentration of
150mM. The lysate was subjected to centrifugation at
13400 g at 4 C for 20min. The supernatant was
incubated with 30ml anti-FLAG M2 agarose at 4 C for
2h. The beads were washed with NET-2 buﬀer as
described above. Precipitated proteins were dissociated
from the beads with sample buﬀer containing 50mM
Tris–HCl, pH 6.8, 100mM dithiothreitol, 2% SDS, 20%
glycerol and 0.2mg/ml bromophenol blue.
To identify TAP-interacting proteins using mass
spectrometry analysis, HEK293 cells grown on a 15-cm
dish at 60–70 % conﬂuency were transfected with 60mg
of plasmid encoding Flag-tagged TAP using
Lipofectamine 2000. Immunoprecipitation using anti-
FLAG was carried out as described above. Precipitated
proteins were separated by 10% SDS-PAGE followed by
SYPR Ruby staining (Bio-Rad) and detected using
Typhoon 9410 (GE Healthcare). The following proce-
dures, including trypsinization and peptides recovery,
were essentially carried out as described (18).
NMD assays and northern blotting
Tet-Oﬀ HeLa cells grown on a 3.5-cm dish were
co-transfected with an MS2 site-containing NMD
reporter (1mg) and an expression vector encoding an
MCP-eﬀector (2.5mg) as well as a control plasmid (bG;
0.5mg). At 24h post-transfection, total RNA was isolated
using TRIzol reagent and subjected to northern blotting
analysis using a
32P-labeled riboprobe complementary to
exon 1 and exon 2 of b-globin. To determine mRNA
half-life, 5mg/ml actinomycin D (Sigma) was added to
inhibit transcription at 10h post-transfection. Cells were
harvested at the indicated time points. For subcellular
fractionation, cells were incubated with gentle lysis
buﬀer (10mM HEPES-KOH, pH 7.4, 10mM NaCl,
3mM MgCl2, 0.5% NP-40) (17) for 5min followed by
centrifugation at 2000 g at 4 C for 8min. The
cytoplasmic and nuclear fraction was collected from the
supernatant and the pellet, respectively. For knockdown
experiments, cells were transfected with 100nM siRNA
for the ﬁrst 48h followed by further transfection with
the eﬀector expression vector and the reporter as above.
After incubation for another 24h, total RNA was isolated
for northern blotting. siRNAs si-TRAP150-J5 and -J8
were purchased from Dharmacon and si-Luciferase
(si-Luc.) and si-TRN were from Invitrogen. Their
sense-strand sequences were as follows: si-TRAP150-J5,
50-gguauaagcuccgagaugauu-30; si-TRAP150-J8,
50-caaaugggagggccugguauu-30; si-Luc.,
50-ggatttcgagtcgtcttaatgtata-30; si-TRN, 50-acaggaaucaac
uuaggaagaugcc-30. Monoclonal anti-TRAN1 was pur-
chased from Sigma. Protein levels were quantiﬁed using
ImageQuantTL software (GE Healthcare).
RESULTS
Association of TRAP150 with TAP
To identify TAP-associating proteins, we transiently
expressed FLAG-tagged TAP in HEK293 cells and
prepared the cell lysate for immunoprecipitation using
an antibody against FLAG peptide. FLAG-TAP-
co-precipitated proteins were detected by SDS-PAGE
using SYPRO Ruby ﬂuorescence followed by
matrix-assisted laser desorption/ionization time-of-ﬂight
mass spectrometry analysis. Identiﬁed proteins included
several nucleoporins, RanGAP1, RNA helicase RHA/
DHX9 and TRAP150 (Figure 1A). The interaction of
FLAG-TAP with endogenous TRAP150 was conﬁrmed
by immunoblotting using anti-TRAP150 (Figure 1B)
and this interaction was resistant to RNase treatment
(see below, for Figure 4B), suggesting that TAP may
directly interact with TRAP150. TRAP150 contains an
arginine/serine-rich sequence in the N-terminal region
and its C-terminal region has 48% overall identity with
BCLAF1/Btf (21), a cell death-promoting transcriptional
repressor (Figure 1C). Within the BCLAF1 homologous
domain, a 90-amino acid segment of TRAP150 shares
30% similarity with MLN51, an EJC core component
(22,23). Both TRAP150 and BCLAF1 are associated
with the spliceosome, indicating their potential role in
3342 Nucleic Acids Research, 2010,Vol.38, No. 10pre-mRNA splicing (4,24). Moreover, the interaction of
TRAP150 with TAP predicts a function for TRAP150
in post-splicing events. Therefore, in this study, we
attempted to explore the potential of TRAP150 in
splicing and subsequent mRNA maturation steps.
Using anti-TRAP150, we observed that TRAP150 was
distributed mainly in the nucleoplasm with higher concen-
trations at discrete foci (Figure 2A). TRAP150 foci
overlapped well with sites stained with anti-SC35
(Figure 2A), indicating that TRAP150 co-localizes with
splicing factors in nuclear speckles. We also performed
an interspecies heterokaryon assay to examine whether
TRAP150 is exported to the cytoplasm. FLAG-tagged
TRAP150 was transiently co-expressed with GFP-
hnRNP A1 or GFP-hnRNP C1 in human HeLa cells.
Transfected cells were subsequently fused with mouse
NIH-3T3 cells. FLAG-TRAP150 was never detected in
the cytoplasm of the fused cells, in contrast to the obser-
vation with hnRNP A1 and hnRNP C1 that were visible
in the cytoplasm at 3 and 16h, respectively, after cell
fusion (Figure 2B). This result indicated that TRAP150
localization is very likely restricted to the nucleus.
TRAP150 activates pre-mRNA splicing
TRAP150 has been identiﬁed in the spliceosome (24), but
whether it plays any role in pre-mRNA splicing is unclear.
To ﬁrst examine whether TRAP150 is essential for
pre-mRNA splicing, we exploited small-interfering RNA
(siRNA)-mediated knockdown to deplete TRAP150 in
HeLa cells. Immunoblotting showed that the protein
level of TRAP150 was reduced to  20% of the mock by
siRNA J5 (Figure 3A, lane 2). The reporter used encoded
the chloramphenicol acetyl transferase (CAT) transcript,
within which the ﬁrst intron of human b-globin was
inserted (18). TRAP150 knockdown resulted in blockage
of the splicing of this reporter transcript (lane 2).
However, another TRAP150 siRNA, J8, that failed to
reduce TRAP150 expression had no eﬀect on splicing
(lane 3), as was the case for siRNA targeting
transportin-1, (lane 4, TRN). Moreover, the splicing
activity of TRAP150-knockdown cells could be restored
by overexpression of a J5-resistant TRAP150, indicating
the speciﬁc role of TRAP150 in pre-mRNA splicing
Figure 2. Cellular localization of human TRAP150. (A) Double immunoﬂuorescence staining of HeLa cells was performed using anti-TRAP150 and
anti-SC35. Co-localized signals are indicated by arrows. Nuclei were stained with Hoechst dye 33258. (B) HeLa cells were co-transfected with the
expression vector encoding FLAG-TRAP150 and a vector encoding GFP-hnRNP A1 or GFP-hnRNP C1. Transfected HeLa cells were fused with
mouse NIH3T3 cells for 3 or 16h in the presence of cycloheximide. Immunoﬂuorescence was performed using anti-FLAG; GFP fusion proteins were
directly visualized by ﬂuorescence microscopy. Arrows indicate mouse cell nuclei.
Figure 1. TRAP150 associates with TAP. HEK 293 cells were trans-
iently transfected with an expression vector encoding FLAG-tagged
TAP or mock-transfected. Cell lysates were subjected to immunopre-
cipitation with anti-FLAG-conjugated resin. (A) Co-precipitated
proteins were detected by SDS-PAGE using SYPRO Ruby. FLAG-
TAP-associated proteins were identiﬁed by mass spectrometry. (B)
Immunoblotting of FLAG-TAP-co-precipitates was performed using
anti-TRAP150. (C) Schematic representation of the TRAP150 domain
structure.
Nucleic Acids Research, 2010,Vol.38, No. 10 3343(Supplementary Figure 1, lane 4). We also prepared the
nuclear extract from TRAP150-depleted HeLa cells and
performed in vitro splicing assay using a
32P-labeled
PIP85a pre-mRNA as substrate. However, a signiﬁcant
reduction of TRAP150 protein level (Figure 3B,
immunoblotting) appeared not to aﬀect pre-mRNA
splicing in vitro (Figure 3B, splicing assay). A similar
result was also observed with another pre-mRNA
derived from the adenovirus major late transcript (data
not shown). Although the possibility that residual
TRAP150 was suﬃcient for pre-mRNA splicing remains,
our present data indicate that TRAP150 is not critical for
pre-mRNA splicing in a cell-free system, but plays a role
in cells. Perhaps transcription is required for TRAP150 to
function in pre-mRNA splicing in vivo; this possibility
remains to be examined.
We next explored whether overexpression of TRAP150
has any eﬀect on splicing. The b-globin intron-containing
CAT reporter was co-transfected with the expression
vector of HA-tagged TRAP150 in HeLa cells.
Overexpression of TRAP150 greatly enhanced the eﬃ-
ciency of reporter pre-mRNA splicing, as compared to
another splicing factor, CA150 (Figure 3C, lanes 2
and 3). BCLAF1 could also promote the splicing of this
reporter, but whether poor expression of BCLAF1
accounted for its lower splicing activity is unclear
Figure 3. TRAP150 activates pre-mRNA splicing. (A) The splicing report pSV40-CAT(In1) encodes the chloramphenicol acetyl transferase, in which
human b-globin intron 1 was inserted. The pSV40-CAT(In1) reporter was co-transfected with indicated siRNA into HeLa cells. RT-PCR was
performed using primers speciﬁc for the reporter exons; the PCR products were analyzed by Southern blotting using primers speciﬁc for the exons
(left). Splicing eﬃciency in individual transfectants was calculated as the intensity of the spliced RNA over the sum of the spliced RNA and the
precursor. Splicing activation fold was obtained from three independent experiments. Immunoblotting using antibodies speciﬁc to indicated protein
was performed to reveal knockdown eﬃciency (right). (B) HeLa cells were mock-transfected or transfected with si-TRAP150 (J5). The nuclear extract
was prepared from transfected cells and analyzed by immunoblotting (upper). Lower panel shows that in vitro splicing using
32P-labeled PIP85a
pre-mRNA in the mock- or TRAP150-depleted nuclear extract. (C) Schematic representation of full-length and truncated TRAP150 proteins.
Domains are depicted as in Figure 1. The pSV40-CAT(In1) vector was co-transfected with an expression vector encoding the indicated eﬀector
into HeLa cells. PCR was performed as in (A); asterisk denotes the precursor/spliced RNA hybrid. Splicing eﬃciency was also calculated as in (A)
and the splicing activation fold relative to the reporter only was indicated below the gel. Immunoblotting using anti-HA shows the expression level of
the eﬀectors; actin was used as the loading control.
3344 Nucleic Acids Research, 2010,Vol.38, No. 10(lane 7). Furthermore, to examine which domain of
TRAP150 contributes to splicing activation, we made
truncation mutants. Deletion of the RS-rich domain
severely impaired the splicing activation ability of
TRAP150 (lane 4), whereas the C-terminally truncated
mutant retained almost full activity (lane 5), indicating
that the RS-rich domain is required for the activity of
TRAP150 in pre-mRNA splicing. Together, the above
assays apparently indicate that TRAP150 acts as a
splicing activator and may participate in a step that is
critical for pre-mRNA splicing in cells but not in the
extract.
TRAP150 binds to spliced mRNA and interacts with
the EJC factors
Previous report has indicated that TRAP150 is a compo-
nent of the spliceosome. Our data showed that TRAP150
played an essential role in splicing of reporter pre-mRNAs
in cells (Figure 3). As TRAP150 also interacts with TAP
(Figure 1), we therefore explored whether TRAP150 joins
the spliceosome and subsequently binds to the spliced
mRNA. Nuclear extracts were prepared from transfected
HEK293 cells that transiently expressed FLAG-tagged
TRAP150 or its truncated non-functional fragment,
NC, for in vitro splicing of the PIP85a pre-mRNA.
The reactions were subsequently subjected to immunopre-
cipitation using anti-FLAG. A substantial amount of the
pre-mRNA was co-precipitated with full-length TRAP150
but not with NC (Figure 4A, lanes 5 and 8). Indeed,
TRAP150 became associated with the pre-mRNA even
without addition of ATP in the splicing reaction,
indicating that TRAP150 joins the pre-mRNP early
during spliceosome assembly (Supplementary Figure 2,
lane 4). In contrast with small nuclear RNP-associated
splicing complexes that reacted with anti-Sm Y12,
TRAP150 bound more preferentially to the spliced
mRNA than the excised intron (compare lane 5 to lane
6). Therefore, TRAP150 might be a component of nuclear
post-splicing mRNP complexes. Nevertheless, TRAP150
also co-precipitated the intronless PIP85a in vitro
(Supplementary Figure 2, lane 12). Thus, consistent with
a previous observation (24), TRAP150 could be associated
with mRNPs independent of splicing.
The association of TRAP150 with the spliced mRNA
promoted us to assess whether it interacts with the EJC and
participates in downstream mRNA metabolic events. To
test this possibility, the HA-tagged TRAP150 expression
vector was co-transfected with vector encoding a FLAG-
tagged splicing, EJC or NMD factor into HEK293 cells.
Anti-FLAG-precipitated proteins from cell lysates were
subjected to immunoblotting with anti-HA. The result
showed that a substantial amount of HA-tagged
TRAP150 was co-precipitated with splicing factors
CA150, SRm160 and RNPS1, and that it also interacted
with several components of the post-splicing EJC or NMD
complex, such as REF, TAP, MLN51 and Upf3b, albeit
minimally with Y14 (Figure 4B). The interactions of
HA-TRAP150 with these factors were speciﬁc because it
was not precipitated in the absence of bait (Figure 4B,
pcDNA). Although the interaction between
FLAG-eIF4AIII and HA-TRAP150 was not detected
(data not shown), a signiﬁcant amount of HA-eIF4AIII
could be co-precipitated with FLAG-TRAP150 using
anti-FLAG (Figure 4B, bottom). Therefore, our data
Figure 4. TRAP150 is associated with the spliced mRNP and the EJC. (A) In vitro splicing using
32P-labeled PIP85a pre-mRNA as substrate was
performed in HEK293 cell nuclear extract that contained overexpressed FLAG-TRAP150 or truncated TRAP150 (NC). Immunoprecipitation was
performed using anti-FLAG or anti-Sm protein (antibody Y12). The autoradiogram shows the splicing reaction and precipitated RNAs. (B) HEK293
cells were transfected with an expression vector encoding HA-TRAP150 and vector encoding the FLAG-tagged proteins as indicated. The bottom
panel shows co-transfection of the vectors encoding FLAG-TRAP150 and HA-eIF4AIII. Immunoprecipitation and immunoblotting were
sequentially performed using anti-FLAG and anti-HA, respectively. Asterisk denotes immunoglobulin heavy chain and below is HA-eIF4AIII.
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mRNA likely through its direct interaction with the EJC.
TRAP150 induces mRNA degradation but is not a
canonical NMD factor
The interaction of TRAP150 with the EJC and NMD
factors implied its potential role in mRNA degradation.
Next, we took advantage of an NMD-tethering assay (17)
to examine the activity of TRAP150 in mRNA surveil-
lance. The reporter b-globin mRNA contained a stop
codon located upstream of the repeated MS2 sites
(Figure 5A, diagram, bUAA-6bs, Ref. 17); expression of
the NMD factor Upf3b that was fused to the bacterio-
phage MS2 coat protein (MCP) triggered degradation of
this reporter mRNA (northern blotting, lane 2). Tethering
Figure 5. TRAP150 promotes mRNA degradation in the tethering NMD assay but is not essential for NMD. (A) Schematic representation of the
b-globin reporter bUAA-6bs that contains the UAA stop codon upstream of six copies of the MS2 coat protein (MCP)-binding site; bG without these
sites was used as a co-transfection reference. The bUAA-6bs and bG vectors were co-transfected with an expression vector encoding the indicated
eﬀector. Northern blotting was performed using a
32P-labeled b-globin probe. In individual transfectants, the intensity of steady-state bUAA-6bs mRNA
was normalized to that of bG. Bars show the relative level of the bUAA-6bs mRNA of MCP-eﬀector transfectants to the unfused MCP. (B) The
tethering NMD assay was performed by co-transfection of the reporter as in (A) and the vector encoding MCP or MCP-fused proteins as indicated. Bars
shown at bottom are as in (A). (C) Schematic representation of the b1 and the 50 splice site mutant b1-50m reporters. These two reporters were each
co-transfected with the MCP or MCP-TRAP150 expression vector. Northern blotting was performed as in (A); a longer exposure of the spliced product
of b1-50m is shown in the outlined rectangle. The steady-state level of the spliced mRNA was normalized to that of the precursor mRNA in individual
transfectants; relative levels of mRNA/pre-mRNA of the MCP-TRAP150 transfectant to the corresponding mock are indicated. (D) The bUAA-6bs and
bG vectors were co-transfected with the MCP or MCP-TRAP150 expression vector for 10h. Cells were collected after addition of actinomycin D for 0, 1
or 3h. Northern blotting was performed as in (A). Bars show the relative level of bUAA-6bs to bG mRNA of each transfectant was normalized to that of
time zero. (E) HeLa cells were transfected with the indicated siRNA for 48h. Subsequently, the b-globin reporter containing (b39) or not containing
(bwt) a translation termination codon UAG in exon 2, as depicted in the scheme, was co-transfected with the reference bG. For lanes 5 and 6, the
expression vector of the dominant-negative Upf1 was co-transfected with the reporters. Northern blotting was performed as in (A). Immunoblotting of
cell lysates was performed using anti-TRAP150, FLAG and anti-actin (bottom).
3346 Nucleic Acids Research, 2010,Vol.38, No. 10of TRAP150 markedly downregulated bUAA-6bs
mRNA expression (lane 3). BCLAF1 could also reduce
bUAA-6bs expression, although it was poorly expressed
(lane 4). Next, we characterized TRAP150 domains
involved in mRNA decay. Using truncated TRAP150
proteins, we found that the C-terminal domain, which
contains an MLN51-like fragment, was essential for
TRAP150 function in mRNA degradation, whereas the
N-terminal RS domain was dispensable for this activity
(Figure 5B, lanes 4 and 5). Therefore, together with the
above observation, our results indicated that the activities
of TRAP150 in pre-mRNA splicing and mRNA degrada-
tion involve its separated domains.
To reduce the arguments that MCP-TRAP150 may
interfere with reporter transcription or induce degradation
of primary transcripts, we had attempted to examine the
expression of reporter pre-mRNAs. However, probably
due to eﬃcient splicing, the bUAA-6bs pre-mRNA
was barely detected by northern blotting even in the
absence of MCP-fusion proteins. Therefore, we created
two reporters, which had relatively poor splicing eﬃ-
ciency, thereby allowing pre-mRNA to be detectable
(Figure 5C, diagram). The b1 reporter was created by
removing the ﬁrst intron from bUAA-6bs. Using this
reporter, we observed that TRAP150 could reduce
the level of the spliced mRNA but not the precursor
(Figure 5C, lanes 1 and 2). Splicing was more severely
blocked, when the 50 splice site dinucleotides of
the remaining intron 2 of b1 were further mutated
(Figure 5C, b1-50m). Nevertheless, the result of the
TRAP150-tethering assay was similar to that observed
with b1, indicating that TRAP150 neither signiﬁcantly
impaired transcription nor degraded pre-mRNA (lanes 3
and 4). Therefore, TRAP150 may trigger mRNA degra-
dation after splicing.
We also attempted to evaluate the kinetics of
TRAP150-mediated mRNA decay. In order to detect
spliced reporter mRNAs, we measured their expression
level at 10h after co-transfection with the vector of
MCP-TRAP150. At 1h after addition of actinomycin D
to arrest transcription,  50% of spliced bUAA-6bs
mRNA was reduced by TRAP150 (Figure 5D, lane 5).
This result also indicated that TRAP150 is involved in
post-transcriptional mRNA decay.
Next, we examined whether TRAP150 is essential for
NMD. Using a reporter containing a PTC in the penulti-
mate exon (Ref. 17; Figure 5E, diagram), we compared
RNAi-mediated knockdown of TRAP150 to over-
expression of the Upf1-R844C mutant that displays a
dominant-negative activity in NMD. In contrast to the
eﬀect of Upf1-R844C overexpression, substantial deple-
tion of TRAP150 did not elicit the reporter mRNA level
(Figure 5E, northern blotting), indicating that TRAP150
is not critical for NMD. In the meantime, we also found
that neither the translation inhibitor cycloheximide nor
the Upf1-R844C mutant could block TRAP150-
tethering-induced degradation of the bUAA-6bs reporter
mRNA (Supplementary Figure 3). Therefore, TRAP150-
induced mRNA decay was dissimilar to canonical NMD
and might not be coupled to translation.
TRAP150-mediated mRNA decay is irrespective of PTC
and occurs in the nucleus
The ﬁnding that TRAP150-mediated mRNA degradation
was distinct from NMD prompted us to examine whether
a translation termination codon located prior to the
eﬀector tethering site is essential. Using the b-globin
mRNA lacking such a stop codon (Figure 6, diagram,
bUAC-6bs; Ref. 17), we observed that, unlike Upf3b,
TRAP150 could induce eﬃcient degradation of this
NMD-insensitive mRNA (Figure 6, lanes 2 and 3).
Therefore, TRAP150-induced mRNA decay might not
necessarily depend on the termination codon upstream
of its tethering site. This result also indicated that
TRAP150 can induce mRNA decay no matter whether
it is tethered within the 30 untranslated region (UTR) or
open reading frame. Thus, TRAP150 could bypass the
requirement for a PTC to elicit degradation of the
tethered mRNA, as does SMG7 (25).
Our above data showed that TRAP150 is restricted to
the nucleus (Figure 2). Thus, it is possible that
TRAP150-activated mRNA decay takes place in the
nucleus. To examine this possibility, we adopted the
tethering assay as above but fractionated transfected
Tet-Oﬀ HeLa cells for analysis. Immunoblotting of
subcellular fractions showed that TRAP150 distributed
only in the nucleus (Figure 7A), consistent with our
immunoﬂuorescence data (Figure 2), whereas Upf3b
was detected in both the cytoplasm and the nucleus
(Figure 7A). As reported (26), tethering of Upf3b led to
degradation of the bUAA-6bs but not bUAC-6bs mRNA
in the cytoplasm (Figure 7B, lanes 2 and 5). In contrast to
that observed with Upf3b, the level of both reporter
mRNAs was signiﬁcantly reduced by tethering of
Figure 6. Premature stop codon is not required for TRAP150-mediated
mRNA decay. The scheme shows the bUAC-6bs reporter, which is
similar to bUAA-6bs except that the UAA codon is changed to
UAC. The TRAP150-tethering assay was performed as in Figure 5B.
The relative level of bUAC-6bs to bG mRNA of the transfectants was
shown as in Figure 5B.
Nucleic Acids Research, 2010,Vol.38, No. 10 3347TRAP150 in the nucleus (Figure 7B, lanes 3 and 6). Thus,
as predicted, TRAP150-induced mRNA decay may occur
in the nucleus, which is also substantially diﬀerent from
NMD.
DISCUSSION
In this report, we show that the spliceosomal component
TRAP150 has a dual function in post-transcriptional
control. TRAP150 can activate pre-mRNA splicing
when overexpressed and plays an essential role in
splicing in vivo. Moreover, when tethered to mRNA tran-
scripts, TRAP150 can induce their degradation in the
nucleus. We propose that TRAP150 functions in nuclear
mRNA processing and mRNA decay.
Role of TRAP150 in pre-mRNA splicing
We identiﬁed TRAP150 by its interaction with
TAP (Figure 1). Previous reports have revealed that
TRAP150 associates with the spliceosomal complexes,
albeit in a transient and heparin-sensitive manner (24).
TRAP150 may directly interact with splicing factors
RNPS1, SRm160, UAP56 and SRrp86 (27).
Consistently, our observation that TRAP150 is
co-localized with splicing factors in nuclear speckles
(Figure 2) also indicates a potential role of TRAP150 in
pre-mRNA splicing.
Indeed, depletion of TRAP150 by siRNA blocked
pre-mRNA splicing in vivo although it had no apparent
eﬀect on splicing in vitro (Figure 3). Previous reports
indicated that TRAP150 may be recruited to emerging
transcripts via its interaction with RNA polymerase
II-associated splicing factors such as CA150 during
transcription (18,28). Using immunoprecipitation, we
observed that TRAP150 became associated with
the pre-mRNA independent of ATP (Supplementary
Figure 2). Therefore, participation of TRAP150 in
pre-mRNA splicing in vivo may require ongoing transcrip-
tion and occur during the early stage of spliceosome
assembly. Moreover, TRAP150 could potently enhance
splicing eﬃciency via its RS domain-containing
N-terminus while overexpressed (Figure 3). However,
our tests toward whether TRAP150 could modulate alter-
native 50 splice site selection of the adenovirus E1A tran-
scripts or alternative exon selection of CD44, a substrate
of its interacting factor SRrp86 (27), did not ﬁnd a role
of TRAP150 in alternative splicing regulation (data
not shown). Therefore, our present data indicate that
TRAP150 has the splicing enhancing capacity in vivo,
but may not be a general alternative splicing regulator.
The questions of how TRAP150 functions in pre-
mRNA splicing and whether it modulates alternative
splicing in a gene-speciﬁc manner still remain to be
investigated.
Role of TRAP150 in mRNA decay
We observed that TRAP150 associated with spliced
mRNAs and interacted with several components of
post-splicing RNP complexes (Figure 4), and it could
induce degradation of spliced mRNA but not pre-
mRNA (Figure 5). However, we also found that
TRAP150-induced mRNA degradation has several
unique features. First, tethering TRAP150 to the bUAC-
6bs and bUAA-6bs reporter mRNAs could induce their
degradation without discrimination (Figures 5 and 6),
which indicates that TRAP150 induces mRNA decay in
a PTC-independent manner. In another words, TRAP150
may degrade an mRNA, regardless of whether it is
tethered within the 30 UTR or within the open reading
frame. We infer that TRAP150-mediated mRNA decay
does not involve decoding of the reading frame by the
ribosome. In accordance with this idea, we also showed
that TRAP150-induced mRNA decay does not depend on
active translation (Supplementary Figure 3). Moreover,
unlike NMD, degradation of TRAP150-tethered
mRNAs occurred in the nucleus (Figure 7). Therefore, it
is possible that TRAP150 is not directly involved in
NMD. To explore which ribonucleases are involved in
TRAP150-induced mRNA decay, we examined three
Figure 7. TRAP150-mediated NMD mRNA decay occurs in the
nucleus. (A) Tet-Oﬀ HeLa cells were transiently transfected with an
expression vector encoding MCP, MCP-Upf3b or MCP-TRAP150.
Immunoblotting of total (T), nuclear (N) or cytoplasmic (C) extract
of transfected HeLa cells was performed using respective antibodies
against lamin, a-tubulin and HA epitope that detected MCP-fusions.
(B) The bUAA/C-6bs reporter assay was performed essentially as in
Figure 5A except that northern blotting was using RNAs prepared
from subcellular fractions. Bars show the relative level of bUAA-6bs
or bUAC-6bs to bG mRNA.
3348 Nucleic Acids Research, 2010,Vol.38, No. 10exonucleases Xrn1, Xrn2 and Rrp6. Depleting one or two
of these nucleases by RNAi had no signiﬁcant eﬀect on
TRAP150-induced RNA degradation (Supplementary
Figure 4). This observation was somewhat intriguing
because these three enzymes constitute the main
ribonucleolytic activity of eukaryotic cells (7). Taken
together, although TRAP150 likely interacts with the
integral EJC (Figure 4), it confers an mRNA degradation
activity that is very diﬀerent from NMD. The mechanism
of how TRAP150 activates mRNA degradation pathways
needs further study.
TRAP150 is a dual function modular protein
Domain deletion analysis showed that truncation of the
RS domain-containing N-terminus of TRAP150 caused a
complete loss of its splicing activation potential but
retained the RNA degradation activity, whereas deletion
of the C-terminal domain had an opposite result
(Figures 3, 5 and 6). This observation indicated that
TRAP150 is a modular protein, in which the respective
splicing activation and RNA degradation activities
involve distinct and separable domains and thereby act
independently. The RS-rich domain of TRAP150 very
likely contributes to its splicing activation activity
(Figure 3), which is similar to that observed with many
SR splicing factors (29). Interestingly, the C-terminal
region of TRAP150 contains a motif homologous to
MLN51 and BCLAF. MLN51 is a critical factor for
NMD (30), whereas TRAP150 is likely involved in
nuclear mRNA decay (Figure 7). Therefore, whether this
conserved motif recruits any critical factors such as
ribonucleases to cause mRNA destruction remains to be
studied. In conclusion, we report here that TRAP150 is a
modular protein with dual post-transcriptional activities
and may provide a link between pre-mRNA spicing and
nuclear degradation of mRNAs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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